Lung Cancer Treatment: Complete Clinical Guide, Benefits & Recovery

Clinical Overview: Understanding Lung Cancer Treatment

Lung Cancer Treatment represents a cornerstone clinical program at Spica Healthcare — Grover Hospital, Bathinda. Supervised directly by Dr. Neha Gupta (Director & Senior Medical Oncologist), this evidence-based pathway integrates sub-millimeter surgical precision, advanced intraoperative 3D navigation, ISO Class-100 Laminar Airflow surgical suites, and personalized accelerated rehabilitation to restore function, eliminate pain, and maximize long-term treatment longevity.

In South-Western Punjab and adjoining regions of Haryana and Rajasthan, patients frequently encounter delayed clinical diagnoses or generalized approaches that fail to address anatomical nuances. At Spica Healthcare, every patient undergoes rigorous digital staging, ensuring that surgical interventions or targeted medical therapies are customized to individual biomechanics and oncological requirements.

Clinical Indications: When is Lung Cancer Treatment Recommended?

• Non-Small Cell Lung Cancer (NSCLC) of any clinical stage (Stage 1 to Stage 4).

• Small Cell Lung Cancer (SCLC) in limited or extensive stage requiring chemo-immunotherapy.

• Lung cancer patients with brain metastases requiring CNS-penetrant targeted TKIs or radiosurgery.

• Persistent cough, coughing up blood (hemoptysis), unexplained shortness of breath, or chest pain.

Step-by-Step Surgical & Clinical Pathway at Grover Hospital

Step 1: EBUS Biopsy & Whole-Body Staging

Endobronchial Ultrasound (EBUS) biopsy, 3T brain MRI, and whole-body FDG PET-CT scan.

Step 2: Molecular Biomarker Profiling

NGS molecular profiling identifying EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, and PD-L1 status.

Step 3: Targeted, Immunological or Surgical Care

Multidisciplinary execution of targeted therapy, chemo-immunotherapy, or VATS keyhole surgical resection.

Step 4: Continuous Oncological Surveillance

Continuous oncological follow-up, respiratory rehabilitation, and long-term surveillance.

Director's Signature Innovation: Comprehensive Multimodal Lung Cancer Treatment

Dr. Neha Gupta coordinates comprehensive multimodal lung cancer care for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Integrating comprehensive upfront Next-Generation Sequencing (NGS) and PD-L1 biomarker profiling, patients with targetable mutations (EGFR, ALK, ROS1, BRAF, MET, RET) receive daily brain-penetrant oral targeted tablets, while those without mutations receive synergistic chemo-immunotherapy or neoadjuvant Nivolumab + chemotherapy prior to minimally invasive VATS lobectomy, achieving unprecedented survival rates.

✔ Upfront NGS Biomarker Testing: Tests all targetable driver mutations before starting systemic therapy

✔ Neoadjuvant Chemo-Immunotherapy: CheckMate-816 protocol shrinking tumors and clearing nodal disease before surgery

✔ Stereotactic Body Radiotherapy (SBRT): High-precision non-invasive radiation for medically inoperable early tumors

✔ Integrated Pulmonology & Thoracic Surgery: Minimally invasive VATS keyhole lung resections

Recovery Timeline & Functional Milestones

Phase 1: Diagnostic Staging & Molecular Panel (Day 1 – 7)

Bronchoscopy/CT biopsy, comprehensive NGS & PD-L1 panel, and whole-body FDG PET-CT staging.

Phase 2: Active Treatment Phase (Month 1 – 3)

Initiation of targeted oral TKI, chemo-immunotherapy in Daycare suite, or curative VATS surgery.

Phase 3: Response Evaluation (Month 3 – 6)

Restaging CT chest and PET-CT scan assessing objective tumor regression and symptom resolution.

Phase 4: Long-Term Maintenance & Remission (Month 6 – Long Term)

Maintenance targeted/immunotherapy schedule and long-term survivorship surveillance.

Frequently Asked Clinical Questions (FAQs)

What is the difference between Small Cell and Non-Small Cell Lung Cancer?

Lung cancer is broadly divided into Non-Small Cell Lung Cancer (NSCLC, ~85% of cases, including adenocarcinoma and squamous cell) and Small Cell Lung Cancer (SCLC, ~15%, aggressive and fast-growing). Treatment for NSCLC depends heavily on genetic mutations and PD-L1 levels, whereas SCLC is treated with combined chemotherapy and immunotherapy.

Can early-stage lung cancer be completely cured?

Yes. Early Stage 1 and 2 lung cancers are cured with minimally invasive Video-Assisted Thoracoscopic Surgery (VATS lobectomy) or Stereotactic Radiotherapy (SBRT), often followed by adjuvant targeted therapy or immunotherapy to prevent recurrence.

Is Lung Cancer Treatment covered under Ayushman Bharat?

Yes, comprehensive lung cancer treatments, chemotherapy, immunotherapy infusions, targeted kinase inhibitors, and inpatient care at Grover Hospital Bathinda are covered 100% cashless under PM-JAY Ayushman Bharat and 30+ private TPAs.

100% Cashless Insurance & PM-JAY Ayushman Bharat Empanelment

At Spica Healthcare — Grover Hospital Bathinda, Lung Cancer Treatment is fully covered under the Government of India's PM-JAY Ayushman Bharat scheme and over 30+ leading private insurance TPAs. Our on-campus insurance coordinator handles all pre-authorization documentation directly with your insurance company, eliminating financial delays. Families can also share digital DICOM CDs and biopsy reports via WhatsApp (+91 95013 73003) for an urgent surgical review.